Immunoglobulin light chain (AL) amyloidosis is a fatal complication of B-cell proliferation secondary to deposition of amyloid fibrils in various organs. Urinary exosomes (UEX) are the smallest of the microvesicles excreted in the urine. Previously, we found UEX of patients with AL amyloidosis contained immunoglobulin light chain (LC) oligomers that patients with multiple myeloma did not have. To further explore the role of the LC oligomers, UEX was isolated from an AL amyloidosis patient with progressive renal disease despite achieving a complete response. LC oligomers were identified. Mass spectrometry (MS) of the UEX and serum identified two monoclonal lambda LCs.
Abstract
Immunoglobulin light chain (AL) amyloidosis is a fatal complication of B-cell proliferation secondary to deposition of amyloid fibrils in various organs. Urinary exosomes (UEX) are the smallest of the microvesicles excreted in the urine. Previously, we found UEX of patients with AL amyloidosis contained immunoglobulin light chain (LC) oligomers that patients with multiple myeloma did not have. To further explore the role of the LC oligomers, UEX was isolated from an AL amyloidosis patient with progressive renal disease despite achieving a complete response. LC oligomers were identified. Mass spectrometry (MS) of the UEX and serum identified two monoclonal lambda LCs.
Proteomics of the trypsin digested amyloid fragments in the kidney by laser microdissection and MS analysis identified a k6 LC. The cDNA from plasma cell clone was from the IGLV-6-57 family and it matched the amino acid sequences of the amyloid peptides. The predicted mass of the peptide product of the cDNA matched the mass of one of the two LCs identified in the UEX and serum. UEX combined with MS were able to identify 2 monoclonal lambda LCs that current clinical methods could not. It also identified the amyloidogenic LC which holds potential for response assessment in the future.
| I N T R O D U C T I O N
Immunoglobulin light chain (AL) amyloidosis is a fatal complication of B-cell or plasma cell clonal proliferation. 1 Unlike multiple myeloma where the disease advances via clonal expansion, AL amyloidosis causes progressive organ damage by the uninterrupted production of amyloidogenic monoclonal immunoglobulin light chains. This means as long as the amyloidogenic light chain (LC) is being produced, the disease is progressing. Current treatment strategies focus primarily on the reduction of the pathologic LC by targeting the clones responsible for LC production. 2, 3 Clinical trials are underway to directly interfere with the amyloid deposits. 4 In AL amyloidosis, hematologic response is measured by the change in serum free light chain (sFLC). Studies have confirmed the achievement of a very good partial response (VGPR) as defined by a difference of the involved to uninvolved free light chain (dFLC) of < 4 mg/dL is associated with improved outcomes. 5 While the sFLC is currently the best biomarker for hematologic assessment, it is far from perfect. 6 First, the assay cannot determine monoclonality directly.
Monoclonality is only inferred by an abnormal ratio. Second, the nor- 
| M E T H O D S
This study was approved by the Mayo Institutional Review Board and was in adherence with the declaration of Helsinki. Consent was obtained from all patients whose blood, serum or bone marrow samples were obtained. Extraction of the cDNA was performed on clonal plasma cells obtained from the bone marrow during diagnostic evaluation using LC specific primers. 10 Proteomics of the amyloid was performed by laser microdissection liquid chromatography tandem MS (LCMS) of the kidney biopsy sample. 11 Proteomics analysis of the trypsin digest was performed using 3 different algorithms.
The complete methods of UEX extraction and fractionation were published previously. 9 UEX were extracted off of 24 hour urine collections. Glomerular, collecting duct, and tubular UEX were separated by density and identified using antibodies to nephron markers. Glomerular Serum protein electrophoresis showed 1.3 g/dL of a monoclonal IgG lambda and a monoclonal lambda. The lambda sFLC was 13.0 mg/dL with a j:k ratio of 0.09 (Supporting Information Table S1 ).
(C-ex5) is a 42 year old healthy female with a creatinine of 0.9 mg/ dL and normal proteinuria of 53 mg/d. This is the negative control. 
| R E S U L T S
In AL-ex1, high molecular weight LC oligomers were found in UEX.
This was our positive control. The Western blot was previous shown. 9 To prove the LC oligomers contained monoclonal light chain, MALDI MS was performed on the high molecular bands which showed a monoclonal k3 LC (Supporting Information Figure S1 ). LC oligomers were not found in the UEX of C-ex5 (the negative control). LC oligomers were also absent from the UEX of AL-ex13 who was in hematologic and renal response. MiRAMM performed on serum of AL-ex13 found a small monoclonal lambda LC but no monoclonal LC in the UEX ( Figure   1 ).
High molecular weight LC oligomers were found in UEX fractions of patient AL-ex11 consistent with active amyloidosis (Figure 2A) . 9 In addition, there were multiple bands of various molecular weights which are fragmentation of the LC oligomers. These high molecular weight oligomeric LCs migrated between fractions 4-6 which were determined to be glomerular in origin by podocin staining ( Figure 2B ). MiRAMM of the UEX identified two monoclonal FLC peaks (23,306 Da and 23,092 Da) both of which were consistent with lambda LCs based on their mass.
These same peaks were also identified in the serum (Figure 3 ). Unfortunately, no more samples were available for further proteomics studies.
LCMS of the tryptic fragments of the amyloid extracted from the kidney identified several amino acid sequences corresponding to the product of a gene from the IGLV-6-57 family (k6 LC). 10 To confirm the prognostic value of the > 250 kDa oligomers, crude UEX analysis was performed on four additional patients (Supporting Information Table S2 ). All of these patients had renal progression despite negative serum and urine immunofixation and normal FLC ratio. All 4 patients had undergone treatment and achieved a CR by definition. Another patient (AL-ex201) was a newly diagnosed AL with equivocal serum immunofixation, negative urine immunofixation and normal FLC ratio. Oligomeric LC species were present in the UEX of all five patients (Supporting Information Figure S2 ).
| DISCUSSION
Treatment of AL amyloidosis has significantly improved in the past decade as a result of more effective and less toxic chemotherapy and better assessment tools. 2, 7, 13 The results from the current study strongly suggest that UEX can be a powerful tool in the assessment of renal response in patients with AL amyloidosis. The LC oligomers present in our positive control ALex1 were also present in the UEX of AL-ex11. In contrast, no oligomeric LC was found in the UEX of C-ex5 our negative control and ALex13 who was in hematologic and renal response. To insure that the LC oligomers were comprised of monoclonal LC, proteomics studies using MALDI was performed on the UEX of AL-ex1. Only monoclonal LC was found in the bands containing the LC oligomers. The evidence strongly suggests the presence of LC oligomers on the UEX is associated with active amyloid formation.
This study also showed that the LC isolated with UEX was indeed the amyloidogenic LC. Using LCMS, the lambda LC in the amyloid deposits was identified as belonging to the k6 family. Amino acid sequences derived from LCMS of the amyloid deposits matched the cDNA isolated from bone marrow plasma cells at the time of diagnosis.
The molecular weight of one of the LCs isolated by UEX and found in the serum matched the molecular weight of the transcript from the cDNA. This is strong evidence that the k6 LC with a mass of 23,306
Da isolated from the UEX is the same LC deposited in the kidney, which is circulating in the blood after it was produced by the plasma cells in the bone marrow.
By MiRAMM, two LCs were identified in the UEX and serum of patient AL-ex11. A LC was also identified in the serum of the AL-ex13.
It is important to note that this was done when both patients were supposed to be in CR. The sensitivity of MiRAMM is far beyond that of the current commercially available methods. 
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